Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Inkwood Research | PRODUCT CODE: 1126323

Cover Image

PUBLISHER: Inkwood Research | PRODUCT CODE: 1126323

Europe Stem Cell Market Forecast 2022-2030

PUBLISHED:
PAGES: 140 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 1600
PDF (Corporate License)
USD 2200

Add to Cart

KEY FINDINGS

The Europe stem cell market is set to grow with a CAGR of 8.60% over the forecast period of 2022 to 2030. The region's market growth is strengthened by the rise in product releases, the increasing incidence of target conditions, the surge in awareness about stem cell-based therapies for different hair and skin disorders, and strategic initiatives like collaborations and agreements.

MARKET INSIGHTS

The Europe stem cell market growth study comprises the evaluation of the United Kingdom, Poland, Italy, France, Belgium, Germany, and Rest of Europe. As per the World Population Ageing report published in 2019, France had 13.28 million people aged 65 years and over. While this number is estimated to reach 16.09 million by 2030, the stem cell market in France is projected to witness substantial growth over the upcoming years, owing to the surge in the geriatric population.

On the other hand, given the rising number of chronic diseases in Italy, investments in research and development for developing effective treatments and clinical trials for stem cell therapy are anticipated to increase significantly. As per the estimations issued by AIRTUM 2020, around 377,000 new cases of malignant tumors were diagnosed in Italy, including 182,000 and 195,000 in women and men, respectively. Furthermore, the COVID-19 pandemic is one of the key factors driving the market demand in Italy. As a result, these factors are set to facilitate the Europe stem cell market growth during the forecast period.

COMPETITIVE INSIGHTS

Some of the main firms operating in the market are: Qiagen, Smith+Nephew PLC, Merck KGaA (Sigma Aldrich), etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation caters to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Product Code: 5142

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. KEY DRIVERS
    • 3.1.1. SURGING DEMAND FOR STEM CELLS IN REGENERATIVE MEDICINE
    • 3.1.2. GROWING R&D INVESTMENTS IN STEM CELL THERAPIES & RESEARCH
    • 3.1.3. RISING AWARENESS ABOUT UMBILICAL CORD STEM CELLS
    • 3.1.4. REDUCED RISK OF TISSUE REJECTION IN TRANSPLANTS
  • 3.2. KEY RESTRAINTS
    • 3.2.1. ABSENCE OF A WELL-DEFINED REGULATORY FRAMEWORK FOR STEM CELL THERAPY
    • 3.2.2. HIGH COSTS ASSOCIATED WITH STEM CELL PROCEDURES
    • 3.2.3. ETHICAL ISSUES AND SOCIAL COMPLEXITIES
    • 3.2.4. LESS RESPONSIVENESS IN DEVELOPED ECONOMIES

4. KEY ANALYTICS

  • 4.1. IMPACT OF COVID-19 ON STEM CELL MARKET
  • 4.2. KEY MARKET TRENDS
  • 4.3. PORTER'S FIVE FORCES ANALYSIS
    • 4.3.1. BUYERS POWER
    • 4.3.2. SUPPLIERS POWER
    • 4.3.3. SUBSTITUTION
    • 4.3.4. NEW ENTRANTS
    • 4.3.5. INDUSTRY RIVALRY
  • 4.4. OPPORTUNITY MATRIX
  • 4.5. VENDOR LANDSCAPE
  • 4.6. VALUE CHAIN ANALYSIS
  • 4.7. KEY BUYING CRITERIA
    • 4.7.1. PRICE
    • 4.7.2. EFFICACY
    • 4.7.3. APPLICATION AND EFFECTIVENESS
    • 4.7.4. ACCURACY
  • 4.8. REGULATORY FRAMEWORK

5. MARKET BY THERAPEUTIC APPLICATION

  • 5.1. ORTHOPEDIC TREATMENTS
  • 5.2. INJURIES & WOUNDS
  • 5.3. ONCOLOGY DISORDERS
  • 5.4. CARDIOVASCULAR DISORDERS
  • 5.5. NEUROLOGICAL DISORDERS
  • 5.6. DIABETES
  • 5.7. OTHER THERAPEUTIC APPLICATIONS

6. MARKET BY PRODUCT

  • 6.1. ADULT STEM CELL
    • 6.1.1. HEMATOPOIETIC STEM CELL
    • 6.1.2. NEURAL STEM CELL
    • 6.1.3. UMBILICAL CORD STEM CELL
    • 6.1.4. MESENCHYMAL STEM CELL
    • 6.1.5. DENTAL STEM CELL
  • 6.2. HUMAN EMBRYONIC STEM CELL
  • 6.3. PLURIPOTENT
  • 6.4. MOUSE/RAT NEURAL

7. MARKET BY TECHNOLOGY

  • 7.1. CELL ACQUISITION
    • 7.1.1. BONE MARROW HARVEST
    • 7.1.2. UMBILICAL CORD
    • 7.1.3. APHERESIS
  • 7.2. CELL PRODUCTION
    • 7.2.1. THERAPEUTIC CLONING
    • 7.2.2. IN VITRO FERTILIZATION (IVF)
    • 7.2.3. CELL CULTURE
    • 7.2.4. ISOLATION
  • 7.3. CRYOPRESERVATION
  • 7.4. EXPANSION & SUB-CULTURE

8. MARKET BY APPLICATION

  • 8.1. REGENERATIVE MEDICINE
  • 8.2. DRUG DISCOVERY AND DEVELOPMENT

9. MARKET BY TREATMENT TYPE

  • 9.1. ALLOGENEIC STEM CELL THERAPY
  • 9.2. AUTOLOGIC STEM CELL THERAPY
  • 9.3. SYNGENEIC STEM CELL THERAPY

10. GEOGRAPHICAL ANALYSIS

  • 10.1. EUROPE
    • 10.1.1. MARKET SIZE & ESTIMATES
    • 10.1.2. KEY GROWTH ENABLERS
    • 10.1.3. KEY CHALLENGES
    • 10.1.4. KEY PLAYERS
    • 10.1.5. COUNTRY ANALYSIS
      • 10.1.5.1. UNITED KINGDOM
      • 10.1.5.2. GERMANY
      • 10.1.5.3. FRANCE
      • 10.1.5.4. ITALY
      • 10.1.5.5. BELGIUM
      • 10.1.5.6. POLAND
      • 10.1.5.7. REST OF EUROPE

11. COMPETITIVE LANDSCAPE

  • 11.1. KEY STRATEGIC DEVELOPMENTS
    • 11.1.1. ACQUISITIONS
    • 11.1.2. PARTNERSHIPS
  • 11.2. COMPANY PROFILES
    • 11.2.1. ALLCELLS LLC
    • 11.2.2. BECTON, DICKINSON AND COMPANY (BD)
    • 11.2.3. CORNING INC
    • 11.2.4. GE HEALTHCARE
    • 11.2.5. INTERNATIONAL STEM CELL CORPORATION
    • 11.2.6. LOREM CYTORI INC
    • 11.2.7. MERCK KGAA (SIGMA ALDRICH)
    • 11.2.8. MILTENYI BIOTEC
    • 11.2.9. PLURI INC
    • 11.2.10. QIAGEN
    • 11.2.11. SMITH+NEPHEW PLC
    • 11.2.12. STEMCELL TECHNOLOGIES INC
    • 11.2.13. STRYKER CORPORATION
    • 11.2.14. TAKARA HOLDINGS INC
    • 11.2.15. THERMO FISHER SCIENTIFIC INC
Product Code: 5142

LIST OF TABLES

  • TABLE 1: EUROPE MARKET SNAPSHOT - STEM CELL
  • TABLE 2: EXAMPLES OF APPROVED CELL THERAPY PRODUCTS
  • TABLE 3: REGULATORY FRAMEWORK
  • TABLE 4: EUROPE STEM CELL MARKET, BY THERAPEUTIC APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 5: EUROPE STEM CELL MARKET, BY THERAPEUTIC APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 6: EUROPE STEM CELL MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 7: EUROPE STEM CELL MARKET, BY PRODUCT, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 8: EUROPE STEM CELL MARKET, BY ADULT STEM CELL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 9: EUROPE STEM CELL MARKET, BY ADULT STEM CELL, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 10: EUROPE STEM CELL MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 11: EUROPE STEM CELL MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 12: EUROPE STEM CELL MARKET, BY CELL ACQUISITION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 13: EUROPE STEM CELL MARKET, BY CELL ACQUISITION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 14: EUROPE STEM CELL MARKET, BY CELL PRODUCTION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 15: EUROPE STEM CELL MARKET, BY CELL PRODUCTION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 16: EUROPE STEM CELL MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 17: EUROPE STEM CELL MARKET, BY APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 18: EUROPE STEM CELL MARKET, BY TREATMENT TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 19: EUROPE STEM CELL MARKET, BY TREATMENT TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 20: EUROPE STEM CELL MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 21: EUROPE STEM CELL MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 22: LEADING PLAYERS OPERATING IN EUROPE STEM CELL MARKET
  • TABLE 23: LIST OF ACQUISITIONS
  • TABLE 24: LIST OF PARTNERSHIPS

LIST OF FIGURES

  • FIGURE 1: KEY MARKET TRENDS
  • FIGURE 2: STEM CELL SCREENING STRATEGIES AND THEIR POTENTIAL APPLICATION
  • FIGURE 3: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 4: OPPORTUNITY MATRIX
  • FIGURE 5: VENDOR LANDSCAPE
  • FIGURE 6: VALUE CHAIN ANALYSIS
  • FIGURE 7: KEY BUYING CRITERIA
  • FIGURE 8: EUROPE STEM CELL MARKET, GROWTH POTENTIAL, BY THERAPEUTIC APPLICATION, IN 2021
  • FIGURE 9: EUROPE STEM CELL MARKET, BY ORTHOPEDIC TREATMENTS, 2022-2030 (IN $ MILLION)
  • FIGURE 10: EUROPE STEM CELL MARKET, BY INJURIES & WOUNDS, 2022-2030 (IN $ MILLION)
  • FIGURE 11: EUROPE STEM CELL MARKET, BY ONCOLOGY DISORDERS, 2022-2030 (IN $ MILLION)
  • FIGURE 12: EUROPE STEM CELL MARKET, BY CARDIOVASCULAR DISORDERS, 2022-2030 (IN $ MILLION)
  • FIGURE 13: EUROPE STEM CELL MARKET, BY NEUROLOGICAL DISORDERS, 2022-2030 (IN $ MILLION)
  • FIGURE 14: EUROPE STEM CELL MARKET, BY DIABETES, 2022-2030 (IN $ MILLION)
  • FIGURE 15: EUROPE STEM CELL MARKET, BY OTHER THERAPEUTIC APPLICATIONS, 2022-2030 (IN $ MILLION)
  • FIGURE 16: EUROPE STEM CELL MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2021
  • FIGURE 17: EUROPE STEM CELL MARKET, BY ADULT STEM CELL MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 18: EUROPE STEM CELL MARKET, GROWTH POTENTIAL, BY ADULT STEM CELL, IN 2021
  • FIGURE 19: EUROPE STEM CELL MARKET, BY HEMATOPOIETIC STEM CELL MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 20: EUROPE STEM CELL MARKET, BY NEURAL STEM CELL MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 21: EUROPE STEM CELL MARKET, BY UMBILICAL CORD STEM CELL MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 22: EUROPE STEM CELL MARKET, BY MESENCHYMAL STEM CELL MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 23: EUROPE STEM CELL MARKET, BY DENTAL STEM CELL MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 24: EUROPE STEM CELL MARKET, BY HUMAN EMBRYONIC STEM CELL, 2022-2030 (IN $ MILLION)
  • FIGURE 25: EUROPE STEM CELL MARKET, BY PLURIPOTENT, 2022-2030 (IN $ MILLION)
  • FIGURE 26: EUROPE STEM CELL MARKET, BY MOUSE/RAT NEURAL, 2022-2030 (IN $ MILLION)
  • FIGURE 27: EUROPE STEM CELL MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021
  • FIGURE 28: EUROPE STEM CELL MARKET, BY CELL ACQUISITION, 2022-2030 (IN $ MILLION)
  • FIGURE 29: EUROPE STEM CELL MARKET, GROWTH POTENTIAL, BY CELL ACQUISITION, IN 2021
  • FIGURE 30: EUROPE STEM CELL MARKET, BY BONE MARROW HARVEST, 2022-2030 (IN $ MILLION)
  • FIGURE 31: EUROPE STEM CELL MARKET, BY UMBILICAL CORD, 2022-2030 (IN $ MILLION)
  • FIGURE 32: EUROPE STEM CELL MARKET, BY APHERESIS, 2022-2030 (IN $ MILLION)
  • FIGURE 33: EUROPE STEM CELL MARKET, BY CELL PRODUCTION, 2022-2030 (IN $ MILLION)
  • FIGURE 34: EUROPE STEM CELL MARKET, GROWTH POTENTIAL, BY CELL PRODUCTION, IN 2021
  • FIGURE 35: EUROPE STEM CELL MARKET, BY THERAPEUTIC CLONING, 2022-2030 (IN $ MILLION)
  • FIGURE 36: EUROPE STEM CELL MARKET, BY IN VITRO FERTILIZATION (IVF), 2022-2030 (IN $ MILLION)
  • FIGURE 37: EUROPE STEM CELL MARKET, BY CELL CULTURE, 2022-2030 (IN $ MILLION)
  • FIGURE 38: EUROPE STEM CELL MARKET, BY ISOLATION, 2022-2030 (IN $ MILLION)
  • FIGURE 39: EUROPE STEM CELL MARKET, BY CRYOPRESERVATION, 2022-2030 (IN $ MILLION)
  • FIGURE 40: EUROPE STEM CELL MARKET, BY EXPANSION & SUB-CULTURE, 2022-2030 (IN $ MILLION)
  • FIGURE 41: EUROPE STEM CELL MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2021
  • FIGURE 42: EUROPE STEM CELL MARKET, BY REGENERATIVE MEDICINE, 2022-2030 (IN $ MILLION)
  • FIGURE 43: EUROPE STEM CELL MARKET, BY DRUG DISCOVERY AND DEVELOPMENT, 2022-2030 (IN $ MILLION)
  • FIGURE 44: EUROPE STEM CELL MARKET, GROWTH POTENTIAL, BY TREATMENT TYPE, IN 2021
  • FIGURE 45: EUROPE STEM CELL MARKET, BY ALLOGENEIC STEM CELL THERAPY, 2022-2030 (IN $ MILLION)
  • FIGURE 46: EUROPE STEM CELL MARKET, BY AUTOLOGIC STEM CELL THERAPY, 2022-2030 (IN $ MILLION)
  • FIGURE 47: EUROPE STEM CELL MARKET, BY SYNGENEIC STEM CELL THERAPY, 2022-2030 (IN $ MILLION)
  • FIGURE 48: EUROPE STEM CELL MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
  • FIGURE 49: UNITED KINGDOM STEM CELL MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 50: GERMANY STEM CELL MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 51: FRANCE STEM CELL MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 52: ITALY STEM CELL MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 53: BELGIUM STEM CELL MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 54: POLAND STEM CELL MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 55: REST OF EUROPE STEM CELL MARKET, 2022-2030 (IN $ MILLION)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!